- Details
- Beyond Endpoints: An interview with Dr Srikala Sridhar, study chair of the BL12 trial Investigator-initiated trials (IITs) often tackle important questions that are not addressed elsewhere. [transcript] Compared with a pharmaceutical company–managed trials, benefits of IITs include generating data in a real-world setting and resolving issues that confound physicians in daily practice. A recent ope...
|
- Details
- Black individuals with muscle-invasive bladder cancer (MIBC) experience 21% lower odds of guideline-based treatment (GBT). Differences in treatment account for 35% of observed Black-White differences in survival. Samuel Washington III, MD, MAS joins Ashish Kamat, MD, MBBS, to highlight this data published in Cancer Medicine. Low GBT levels demonstrated an "under-allocation" of GBT to those who nee...
|
- Details
- Michiel Van der Heijden MD, PhD, joins Ashish Kamat, MD, MBBS discussing the evolution of the guidelines for advanced urothelial cancer. Michiel Van der Heijden provides a concise summary of the European Association of Urology Guidelines and the ESMO guidelines, contrasting statements between the two for patients in first-line treatment who are ineligible to receive cisplatin-based chemotherapy in...
|
- Details
- A new first-line standard of care -- JAVELIN Bladder 100 Platinum-based chemotherapy is currently the standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall survival are limited by chemotherapy resistance. In this Journal Club, Christopher Wallis, MD, PhD, and Zachary Klaassen, MD, MSc review the JAVELIN Bladder 100 randomized, phase...
|
- Details
- Shilpa Gupta, MD presents data from ASCO 2020 on bladder cancer in this discussion with Ashish Kamat, MD, MBBS. Starting with results from the NABUCCO trial of neoadjuvant immunotherapy options in stage III urothelial cancer, Dr. Gupta highlights the results from the trial showing complete responses in 46% of patients. She surveys other trials presented at the 2020 ASCO meeting, including KEYNOTE-...
|
- Details
- Arlene Siefker-Radtke joins Tom Keane to discuss personalized therapy for the treatment of metastatic urothelial cancer with erdafitinib. Dr. Siefker-Radtker outlines the importance of understanding the underlying biologies and mutation patterns that encompass the multiple diseases that makeup bladder cancer. When taking this into consideration, she gives an overview of the tolerance and safety pr...
|
- Details
- Petros Grivas, MD, PhD, joins Alicia Morgans, MD, MPH, to review updates from the virtual ASCO 2020 meeting in the muscle-invasive bladder cancer setting. Dr. Grivas first provides an overview of the IMvigor010 trial which showed that disease-free survival was not prolonged with the addition of atezolizumab after neoadjuvant therapy in patients with muscle-invasive disease. The JAVELIN 100 trial,...
|
- Details
- Alicia Morgans, MD, MPH, and Petros Grivas, MD, PhD, discuss the recent updates in the metastatic urothelial carcinoma (mUC) disease space. Together they discuss multiple presentations given during the virtual ASCO 2020 including the IMvigor010 trial. They discuss other adjuvant immunotherapy trials for mUC, as well as new results from IMvigor130 assessing biomarkers. Dr. Morgans and Dr. Grivas al...
|
- Details
- Cora Sternberg, MD, FACP, an investigator on the phase 3 JAVELIN Bladder 100 trial shares the study design, rationale, and key outcomes from the trial. The JAVELIN Bladder 100 trial is a phase 3 randomized study for maintenance avelumab therapy in patients who derived disease response or stabilization from first-line platinum-based chemotherapy for advanced urothelial cancer. In this conversation...
|
- Details
- The phase III JAVELIN Bladder 100 trial was the first urothelial carcinoma plenary session at an ASCO annual meeting in the meeting's history and Thomas Powles lead principal investigator on the trial along with Matthew Galsky join Alicia Morgans sharing results of this trial. This was a maintenance trial where first-line treatment with avelumab extended the survival over best supportive care (BSC...
|
